These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 27603572)

  • 1. Advances and challenges in hereditary cancer pharmacogenetics.
    Cascorbi I; Werk AN
    Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):73-82. PubMed ID: 27603572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
    Bosch TM; Meijerman I; Beijnen JH; Schellens JH
    Clin Pharmacokinet; 2006; 45(3):253-85. PubMed ID: 16509759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
    Wellmann R; Borden BA; Danahey K; Nanda R; Polite BN; Stadler WM; Ratain MJ; O'Donnell PH
    Cancer; 2018 Jul; 124(14):3052-3065. PubMed ID: 29742281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of anti-cancer drugs: State of the art and implementation - recommendations of the French National Network of Pharmacogenetics.
    Quaranta S; Thomas F
    Therapie; 2017 Apr; 72(2):205-215. PubMed ID: 28262261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics.
    Deeken JF; Figg WD; Bates SE; Sparreboom A
    Anticancer Drugs; 2007 Feb; 18(2):111-26. PubMed ID: 17159598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics in cancer therapy - 8 years of experience at the Institute for Oncology and Radiology of Serbia.
    Cavic M; Krivokuca A; Boljevic I; Brotto K; Jovanovic K; Tanic M; Filipovic L; Zec M; Malisic E; Jankovic R; Radulovic S
    J BUON; 2016; 21(5):1287-1295. PubMed ID: 27837635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics in cancer treatment.
    Nagasubramanian R; Innocenti F; Ratain MJ
    Annu Rev Med; 2003; 54():437-52. PubMed ID: 12525681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
    Cecchin E; De Mattia E; Ecca F; Toffoli G
    Drug Resist Updat; 2018 Jul; 39():18-40. PubMed ID: 30075835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics in the cancer clinic: from candidate gene studies to next-generation sequencing.
    Guchelaar HJ; Gelderblom H; van der Straaten T; Schellens JH; Swen JJ
    Clin Pharmacol Ther; 2014 Apr; 95(4):383-5. PubMed ID: 24448475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of pharmacogenetics in capecitabine efficacy and toxicity.
    Lam SW; Guchelaar HJ; Boven E
    Cancer Treat Rev; 2016 Nov; 50():9-22. PubMed ID: 27569869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using pharmacogene polymorphism panels to detect germline pharmacodynamic markers in oncology.
    Hertz DL; McLeod HL
    Clin Cancer Res; 2014 May; 20(10):2530-40. PubMed ID: 24831276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomic biomarkers for personalized cancer treatment.
    Rodríguez-Antona C; Taron M
    J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline variants in cancer therapy.
    Kaehler M; Cascorbi I
    Cancer Drug Resist; 2019; 2(1):18-30. PubMed ID: 35582146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics and pharmacogenomics as tools in cancer therapy.
    Rodríguez-Vicente AE; Lumbreras E; Hernández JM; Martín M; Calles A; Otín CL; Algarra SM; Páez D; Taron M
    Drug Metab Pers Ther; 2016 Mar; 31(1):25-34. PubMed ID: 26863347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics and cancer therapy.
    Relling MV; Dervieux T
    Nat Rev Cancer; 2001 Nov; 1(2):99-108. PubMed ID: 11905809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacogenomic approaches for prevention of drug toxicity in cancer chemotherapy].
    Hasegawa Y
    Gan To Kagaku Ryoho; 2003 Mar; 30(3):325-33. PubMed ID: 12669388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anticancer drug dosing--pharmacogenomic biomarkers or body surface area?].
    Lehne G; Bjørheim J; Saeter G
    Tidsskr Nor Laegeforen; 2007 Apr; 127(8):1040-4. PubMed ID: 17457389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PharmFrag: An Easy and Fast Multiplex Pharmacogenetics Assay to Simultaneously Analyze 9 Genetic Polymorphisms Involved in Response Variability of Anticancer Drugs.
    Bouvet R; Verdier MC; El Baroudi Y; Galibert MD; David V; Schutz S; Tron C
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.
    Bertholee D; Maring JG; van Kuilenburg AB
    Clin Pharmacokinet; 2017 Apr; 56(4):317-337. PubMed ID: 27641154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [SNPs associated with adverse effects].
    Isomura M; Miki Y
    Gan To Kagaku Ryoho; 2005 Nov; 32(12):1908-13. PubMed ID: 16282725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.